Epstein-Barr Virus Infection

The Epstein–Barr virus (EBV) was discovered 36 years ago by electron microscopy of cells cultured from Burkitt's lymphoma tissue by Epstein, Achong, and Barr.1 Four years later, in 1968, EBV was shown to be the etiologic agent of heterophile-positive infectious mononucleosis.2 EBV DNA was detected in tissues from patients with nasopharyngeal carcinoma in 1970.3 In the 1980s, EBV was found to be associated with non-Hodgkin's lymphoma and oral hairy leukoplakia in patients with the acquired immunodeficiency syndrome (AIDS).4,5 Since then, EBV DNA has been found in tissues from other cancers, including T-cell lymphomas and Hodgkin's disease.6,7 EBV is . . .

[1]  S. Maruo,et al.  Oncogenic Role of Epstein-Barr Virus-Encoded RNAs in Burkitt’s Lymphoma Cell Line Akata , 1999, Journal of Virology.

[2]  E. Kieff,et al.  Epstein-barr virus-induced posttransplant lymphoproliferative disorders , 1999 .

[3]  R. Gascoyne,et al.  Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation , 1999, The Lancet.

[4]  N. Raab-Traub,et al.  Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. , 1999, Science.

[5]  J. Cohen,et al.  Epstein-Barr Virus BARF1 Protein Is Dispensable for B-Cell Transformation and Inhibits Alpha Interferon Secretion from Mononuclear Cells , 1999, Journal of Virology.

[6]  Richard E. Slaughter,et al.  Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. Burrows,et al.  Vaccine strategies against Epstein‐Barr virus‐associated diseases: lessons from studies on cytotoxic T‐cell‐mediated immune regulation , 1999, Immunological reviews.

[8]  S. Tangye,et al.  Cutting edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. , 1999, Journal of immunology.

[9]  R. Spaete,et al.  Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. , 1999, Vaccine.

[10]  S. Rowland-Jones,et al.  A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. , 1999, Journal of immunology.

[11]  S. Burrows,et al.  X-Linked Agammaglobulinemia Patients Are Not Infected with Epstein-Barr Virus: Implications for the Biology of the Virus , 1999, Journal of Virology.

[12]  R. Busuttil,et al.  Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. , 1998, Transplantation.

[13]  B. Wood,et al.  Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. , 1998, Transplantation.

[14]  A. Fischer,et al.  Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. , 1998, Blood.

[15]  D. Allen,et al.  The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM , 1998, Nature.

[16]  V. Godfrey,et al.  Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Anderson,et al.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. , 1998, Immunity.

[18]  D. Thorley-Lawson,et al.  EBV persistence in memory B cells in vivo. , 1998, Immunity.

[19]  D. Srivastava,et al.  Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients , 1998 .

[20]  D. Liebowitz.  Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. , 1998, The New England journal of medicine.

[21]  G. Ogg,et al.  Direct Visualization of Antigen-specific CD8+T Cells during the Primary Immune Response to Epstein-Barr Virus In Vivo , 1998, The Journal of experimental medicine.

[22]  G. Hale,et al.  Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. , 1998, Blood.

[23]  S Kimbrough,et al.  Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. , 1998, Blood.

[24]  N. Lapointe,et al.  Natural history of Epstein-Barr virus infection in a prospective pediatric cohort born to human immunodeficiency virus-infected mothers. , 1998, Journal of Infectious Diseases.

[25]  H. Heslop,et al.  Immunotherapy for Epstein-Barr virus-associated cancers. , 1998, Journal of the National Cancer Institute. Monographs.

[26]  Kirk A Easley,et al.  Natural history of primary Epstein-Barr virus infection in children of mothers infected with human immunodeficiency virus type 1 ♦ 853 , 1998, Pediatric Research.

[27]  C. Scully,et al.  Oral hairy leukoplakia: clinicopathologic features, pathogenesis, diagnosis, and clinical significance. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  J. Reyes,et al.  Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  A Ciechanover,et al.  Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Kliger,et al.  Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. , 1997, Transplantation.

[31]  J. Cohen.  Epstein-Barr virus and the immune system. Hide and seek. , 1997, JAMA.

[32]  R. Johnson,et al.  An animal model for acute and persistent Epstein-Barr virus infection. , 1997, Science.

[33]  K. Pollok,et al.  Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. , 1997, Transplantation.

[34]  K. Lucas,et al.  Biology and adoptive cell therapy of Epstein‐Barr virus‐associated lymphoproliferative disorders in recipients of marrow allografts , 1997, Immunological reviews.

[35]  Qingxue Li,et al.  Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes , 1997, Journal of virology.

[36]  H. Herbst,et al.  EPSTEIN–BARR VIRUS (EBV) INFECTION IN INFECTIOUS MONONUCLEOSIS: VIRUS LATENCY, REPLICATION AND PHENOTYPE OF EBV‐INFECTED CELLS , 1997, The Journal of pathology.

[37]  T. Starzl,et al.  Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. , 1997, Transplantation.

[38]  M. Kersten,et al.  Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma. , 1997, The Journal of clinical investigation.

[39]  D. Moss,et al.  Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. , 1997, Annual review of immunology.

[40]  L. Larocca,et al.  Diagnosis of AIDS-related focal brain lesions , 1997, Neurology.

[41]  P. Brousset,et al.  Epstein‐Barr virus‐associated Hodgkin's disease: Epidemiologic characteristics in international data , 1997, International journal of cancer.

[42]  A. Rickinson,et al.  Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. , 1996, The Journal of infectious diseases.

[43]  R. Fisher,et al.  Aggressive treatment for postcardiac transplant lymphoproliferation. , 1995, Blood.

[44]  Kathryn Flynn,et al.  Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. , 1995, The New England journal of medicine.

[45]  C. Ware,et al.  The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family , 1995, Cell.

[46]  E. Kieff,et al.  Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. , 1995, Immunity.

[47]  H. Stein,et al.  Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. , 1995, Blood.

[48]  J. Locker,et al.  The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. , 1995, The New England journal of medicine.

[49]  R. Parmley,et al.  Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS. , 1995, The New England journal of medicine.

[50]  E. Kieff,et al.  Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1 , 1995, Journal of virology.

[51]  L. Young,et al.  Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state , 1994, Journal of virology.

[52]  T. Osato,et al.  Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[53]  S. Riddler,et al.  Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. , 1994, Blood.

[54]  M. Rowe,et al.  Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[55]  G. Tosato,et al.  Interleukin-6 production in posttransplant lymphoproliferative disease. , 1993, The Journal of clinical investigation.

[56]  B. Nathwani,et al.  Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. , 1993, Blood.

[57]  T. Starzl,et al.  Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. , 1992, The New England journal of medicine.

[58]  L. Young,et al.  Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. , 1992, Virology.

[59]  R. Ambinder,et al.  Epstein-Barr virus in AIDS-related primary central nervous system lymphoma , 1991, The Lancet.

[60]  G. Fleisher,et al.  Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. , 1991, The Journal of infectious diseases.

[61]  B. Nathwani,et al.  Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin's lymphoma. , 1991, Blood.

[62]  J. Cohen.  Epstein‐Barr Virus Lymphoproliferative Disease Associated with Acquired Immunodeficiency , 1991, Medicine.

[63]  T. Mosmann,et al.  Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. , 1990, Science.

[64]  G. Inghirami,et al.  Down-regulation of LFA-1 adhesion receptors by C-myc oncogene in human B lymphoblastoid cells. , 1990, Science.

[65]  T. Mosmann,et al.  Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. , 1990, Science.

[66]  E. Kieff,et al.  Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23 , 1990, Journal of virology.

[67]  N. Harris,et al.  Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. , 1989, The New England journal of medicine.

[68]  R. Warnke,et al.  Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. , 1989, The New England journal of medicine.

[69]  M. Rowe,et al.  Epstein‐barr virus‐infected b cells persist in the circulation of acyclovir‐treated virus carriers , 1989, International journal of cancer.

[70]  I. Ernberg,et al.  Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[71]  M. Allday,et al.  ROLE OF EPITHELIUM IN EBV PERSISTENCE AND PATHOGENESIS OF B-CELL TUMOURS , 1988, The Lancet.

[72]  James F. Jones,et al.  T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. , 1988, The New England journal of medicine.

[73]  S. Straus.  The chronic mononucleosis syndrome. , 1988, The Journal of infectious diseases.

[74]  L. Resnick,et al.  Regression of oral hairy leukoplakia after orally administered acyclovir therapy. , 1988, JAMA.

[75]  D. Purtilo,et al.  Epstein-Barr virus infections in males with the X-linked lymphoproliferative syndrome. , 1987, Annals of internal medicine.

[76]  R. Redfield,et al.  Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. , 1986, The New England journal of medicine.

[77]  A. Scott,et al.  Enzyme-linked immunosorbent assay of antibodies to Epstein-Barr virus nuclear and early antigens in patients with infectious mononucleosis and nasopharyngeal carcinoma. , 1986, Annals of internal medicine.

[78]  W. Andiman,et al.  OPPORTUNISTIC LYMPHOPROLIFERATIONS ASSOCIATED WITH EPSTEIN-BARR VIRAL DNA IN INFANTS AND CHILDREN WITH AIDS , 1985, The Lancet.

[79]  E. Lennette,et al.  Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. , 1985, The New England journal of medicine.

[80]  E. Kieff,et al.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells , 1985, Cell.

[81]  M. Epstein,et al.  Protection of cottontop tamarins against Epstein–Barr virus-induced malignant lymphoma by a prototype subunit vaccine , 1985, Nature.

[82]  M. Epstein,et al.  A re‐examination of the epstein‐barr virus carrier state in healthy seropositive individuals , 1985, International journal of cancer.

[83]  P. A. Biro,et al.  Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[84]  D. Reisman,et al.  A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[85]  N. Raab-Traub,et al.  Epstein-Barr virus replication in oropharyngeal epithelial cells. , 1984, The New England journal of medicine.

[86]  T. Starzl,et al.  REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPY , 1984, The Lancet.

[87]  N. Raab-Traub,et al.  Replication of Epstein–Barr virus in human epithelial cells infected in vitro , 1983, Nature.

[88]  R. Schooley,et al.  Central-nervous-system lymphoma related to Epstein-Barr virus. , 1983, The New England journal of medicine.

[89]  E. Lennette,et al.  OUTBREAK OF BURKITT'S-LIKE LYMPHOMA IN HOMOSEXUAL MEN , 1982, The Lancet.

[90]  Yu Wang,et al.  Serological mass survey for early detection of nasopharyngeal carcinoma in wuzhou city, china , 1982, International journal of cancer.

[91]  N. Day,et al.  Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study , 1978, Nature.

[92]  L. Elveback,et al.  Infectious mononucleosis in Rochester, Minnesota, 1950 through 1969. , 1973, American journal of epidemiology.

[93]  G. Klein,et al.  Epstein–Barr Virus in Burkitt's Lymphoma and Nasopharyngeal Carcinoma: EBV DNA in Biopsies of Burkitt Tumours and Anaplastic Carcinomas of the Nasopharynx , 1970, Nature.

[94]  M. Epstein,et al.  VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. , 1964, Lancet.

[95]  E. Kieff.  Epstein-Barr virus and its replication , 1996 .

[96]  C. Chu,et al.  First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. , 1995, Developments in biological standardization.

[97]  J. Meier,et al.  Epstein-Barr Virus Infections: Biology, Pathogenesis, and Management , 1993, Annals of Internal Medicine.

[98]  S. Hamilton-Dutoit,et al.  The association of Epstein-Barr virus (EBV) with T cell lymphoproliferations and Hodgkin's disease: two new developments in the EBV field. , 1993, Advances in cancer research.

[99]  S. Hamilton-Dutoit,et al.  AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. , 1991, The American journal of pathology.

[100]  V. Diehl,et al.  Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. , 1968, Proceedings of the National Academy of Sciences of the United States of America.